Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.47
-0.0100-0.40%
Post-market: 2.45-0.0200-0.81%19:58 EDT
Volume:4.71M
Turnover:11.52M
Market Cap:2.11B
PE:-3.99
High:2.50
Open:2.47
Low:2.39
Close:2.48
Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Scienture, ARS Pharma, BrightSpring Health

Reuters
·
06 Mar

HC Wainwright Initiates Coverage on ImmunityBio With Buy Rating, $8 Price Target

MT Newswires Live
·
06 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Allegro, MicroSystems, Zscaler

Reuters
·
06 Mar

BUZZ-H.C. Wainwright starts coverage of ImmunityBio with 'buy' rating

Reuters
·
06 Mar

ImmunityBio initiated with a Buy at H.C. Wainwright

TIPRANKS
·
06 Mar

Immunitybio, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
06 Mar

US High Growth Tech Stocks to Watch in March 2025

Simply Wall St.
·
05 Mar

Stock Track | ImmunityBio Soars 5.26% as Earnings Beat Expectations Despite Revenue Miss

Stock Track
·
05 Mar

Stock Track | ImmunityBio, Inc. Shares Plummet 5.09% as Earnings Disappoint Despite EPS Beat

Stock Track
·
04 Mar

ImmunityBio Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
04 Mar

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
03 Mar

ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
03 Mar

ImmunityBio's Q4 Net Loss Narrows, Revenue Rises

MT Newswires Live
·
03 Mar

Earnings Flash (IBRX) ImmunityBio Posts Q4 Net Loss $-0.09 a Share, vs. FactSet Est of $-0.20 Loss

MT Newswires Live
·
03 Mar

ImmunityBio Q4 2024 GAAP EPS $(0.09) Beats $(0.20) Estimate, Sales $7.55M Miss $7.82M Estimate, Cash And Cash Equivalents, And Marketable Securities Of $149.8M

Benzinga
·
03 Mar

Immunitybio Q4 Net Income USD -59.179 Million

THOMSON REUTERS
·
03 Mar

Immunitybio Q4 Operating Income USD -69.4 Million

THOMSON REUTERS
·
03 Mar

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024

Business Wire
·
03 Mar

ImmunityBio Shares Up, FDA Gives RMAT Designation for Treatment of Lymphopenia in Cancer Patients

Dow Jones
·
01 Mar

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 Feb